A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

Recruiting now. Registry record last updated July 15, 2026.

Who can join: Adults 18 to 75, have fatty liver disease (MASLD), BMI 25+.
What you take: Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The study runs about 14 months.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 1Sponsor University of New MexicoDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 8

What this study is for

Primary condition: MASLD. Also studied in: Obesity.

Full scientific study title: Effect of Tirzepatide on Markers of MASLD in Patients With Obesity.

Who can join

Age18 to 75SexAnyBMI25 or higher

Adults 18 to 75, have fatty liver disease (MASLD), BMI 25+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Men and women
Age 18-75
Diagnosis of MASLD based on the following criteria:
Presence of at least 1 out of the 5 following cardiometabolic criteria:
BMI \>25 kg/m2 OR waist circumference \>94 cm (men) or 80 cm (women)

Key exclusion criteria

Pregnancy or breast feeding
Premenopausal women not on any form of contraception
Reports alcohol intake \>50g/day or 350g/week for women and \>60g/day or 420g/week for men or an AUDIT score \>8
Other identifiable causes of steatosis
Documented allergic reaction to tirzepatide or any other GLP1 RA

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

New Mexico1 site

University of New Mexico Health Sciences Center
Albuquerque, New Mexico
Kristen Gonzales, MD505-272-3840KrGonzales@salud.unm.edu

Follow this trial

We email you if NCT06934642 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: June 30, 2025. Expected completion: August 2026. Last updated on ClinicalTrials.gov: July 15, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.